QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, ...

Qiagen NV (QGEN) Q1 2026 Earnings Call Highlights: Navigating Mixed Sales with Strong Profitability

Despite challenges in QuantiFERON sales and US life sciences caution, Qiagen NV (QGEN) maintains robust profitability and outlines strategic growth plans.
Stocktwits on MSN

QGEN stock slumps after-hours on guidance cut tied to weak TB test demand

The company said that it expects 2026 net sales growth of 1-2% now, previously estimated at atleast 5%. ・The company pinned the lowered guidance on sustained caution among U.S. Life Sciences customers ...
Hosted on MSN

Qiagen cuts 2026 outlook as TB test demand slumps

Qiagen has lowered its 2026 sales growth forecast to 1–2% from at least 5%, citing weak demand for its QuantiFERON tuberculosis test, cautious U.S. Life Sciences spending, and geopolitical uncertainty ...
Seeking Alpha

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin ...